Journal DOI 10.68956/journal.human-performance-futures

Creative Commons source reading · Musculoskeletal and tissue health

Orthobiologics in anterior cruciate ligament injuries

Bouchard MD; Rocha De Faria JL; Vinagre G; Pavão DM; Merchan N; Papakostas E; Moatshe G; Bernáldez Domínguez P; Marín Fermín T; Dallo I; Hantouly A

Originally published in J Exp Orthop · 2026-07-01

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

AbstractAnterior cruciate ligament (ACL) injury remains a major challenge in sports medicine because it affects a young and active population and is associated with instability, secondary meniscal and chondral damage, delayed return to sport and post‐traumatic osteoarthritis. This narrative review provides an ACL‐specific overview of orthobiologics, with an emphasis on the biologic rationale, current clinical applications and the strength of the available evidence. The biologic limitations of the native ACL, particularly its poor intrinsic healing capacity in the intra‐articular environment, have spurred interest in strategies to improve graft ligamentization, tendon–bone healing, modulation of inflammation and preservation of native ligament tissue. Platelet‐rich plasma is the most widely investigated orthobiologic in ACL surgery;…

Practical clinical implications

At present, orthobiologics in ACL surgery should be viewed as adjuncts rather than replacements for sound surgical technique, graft selection, tunnel positioning, fixation and structured rehabilitation. For most surgeons performing standard primary ACLR, the available evidence does not support routine universal use of PRP or BMAC solely to improve final patient‐reported outcomes. That said, selective application may be reasonable. Examples include revision settings, cases with biologic concern at the tendon–bone interface, research protocols or repair‐preservation strategies in carefully chosen proximal tears. Even in these situations, the rationale for use should be explicit and expectations should remain realistic. The most clinically compelling biologic signal in ACL surgery currently comes from scaffold‐based repair, particularly…

CONCLUSIONS

Orthobiologics have become an increasingly important part of the scientific conversation surrounding ACL injury, reconstruction and repair. However, the literature should be interpreted through an ACL‐specific lens rather than as a general discussion of regenerative medicine. PRP remains the most studied orthobiologic in ACLR, but its clinical benefits appear inconsistent and generally modest. BMAC is promising but remains insufficiently defined and incompletely validated. Cell‐based therapies from adipose and synovial sources are investigational. In contrast, scaffold‐based biologic repair strategies, especially BEAR, have provided the strongest clinical support for orthobiologic principles in ACL preservation. The field is therefore promising, but not yet mature. The next advances will depend not simply on adding more biologics, but…

Editorial reading guide

  • How were injury, recovery and exposure defined and verified?
  • Which criteria support progression, and what finding should stop or change the plan?